| Senior Doc, Tennessee Pc | |
|
2592 N Santiago Blvd Orange CA 92867-1862 | |
| (855) 434-7763 | |
| Not Available |
| Full Name | Senior Doc, Tennessee Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 2592 N Santiago Blvd, Orange, California |
| Authorized Official Name and Position | John Mark Geiss (CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 8554347763 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Senior Doc, Tennessee Pc 2592 N Santiago Blvd Orange CA 92867-1862 Ph: (855) 434-7763 | Senior Doc, Tennessee Pc 2592 N Santiago Blvd Orange CA 92867-1862 Ph: (855) 434-7763 |
| NPI Number | 1568148351 |
|---|---|
| Provider Enumeration Date | 06/26/2023 |
| Last Update Date | 08/01/2023 |
| Medicare PECOS PAC ID | 5991169070 |
|---|---|
| Medicare Enrollment ID | O20230907001854 |
News Archive
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
The Barth Syndrome Foundation recently announced awardees from its 2017 grant cycle. Miriam Greenberg, Ph.D., professor of biological sciences in the College of Liberal Arts and Sciences at Wayne State University and a resident of Ann Arbor, Michigan, received a one-year, $50,000 grant for the project, "Cardiolipin activates pyruvate dehydrogenase (PDH) - a potential new target for treatment of Barth syndrome."
Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.
The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.
The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568148351 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | John M Geiss |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053651497 PECOS PAC ID: 5890933071 Enrollment ID: I20230919000072 |
News Archive
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
The Barth Syndrome Foundation recently announced awardees from its 2017 grant cycle. Miriam Greenberg, Ph.D., professor of biological sciences in the College of Liberal Arts and Sciences at Wayne State University and a resident of Ann Arbor, Michigan, received a one-year, $50,000 grant for the project, "Cardiolipin activates pyruvate dehydrogenase (PDH) - a potential new target for treatment of Barth syndrome."
Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.
The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.
The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.
› Verified 5 days ago
News Archive
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
The Barth Syndrome Foundation recently announced awardees from its 2017 grant cycle. Miriam Greenberg, Ph.D., professor of biological sciences in the College of Liberal Arts and Sciences at Wayne State University and a resident of Ann Arbor, Michigan, received a one-year, $50,000 grant for the project, "Cardiolipin activates pyruvate dehydrogenase (PDH) - a potential new target for treatment of Barth syndrome."
Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.
The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.
The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.
› Verified 5 days ago
Zhihong Acupuncture Clinic Co Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2950 N Glassell St,, Suite B, Orange, CA 92865 Phone: 714-858-0952 Fax: 714-998-6499 | |
Senior Doc Wyoming, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2592 N Santiago Blvd, Orange, CA 92867 Phone: 855-434-7763 | |
Regenerative Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 615 E Chapman Ave, Orange, CA 92866 Phone: 714-639-4012 Fax: 714-639-4018 | |
Trucare Health Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1234 W Chapman Ave, Ste# 101, Orange, CA 92868 Phone: 714-883-1604 | |
Western Hospitalists Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 655 S Main St, Ste. 306, Orange, CA 92868 Phone: 714-397-0844 | |
Geiss Med Nevada Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2592 N Santiago Blvd, Orange, CA 92867 Phone: 855-434-7763 | |
Coastal Dream Docs Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2860 N Santiago Blvd, Ste 110, Orange, CA 92867 Phone: 949-645-0000 Fax: 949-645-0003 |